TGFBR2 and prostate carcinoma: Finally, a TGFBR2-based CSR, which signals through 4-1BB (TGFBR2:4-1BB), enhanced the anti-tumor function of prostate cancer targeted CAR T cells [221], as well as NY-ESO-1 TCR+ T cells for melanoma [223].